Larry OG (CBD): A Comprehensive Strain Guide

Introduction

Larry OG (CBD) is a contemporary, CBD-forward take on the classic Larry OG (also known as Lemon Larry), crafted for consumers seeking the iconic OG bouquet with a gentler, more balanced effect profile. While the original Larry OG became known for its potent THC and citrus-pine “gas,” this CBD variant emphasizes a more even cannabinoid ratio without abandoning the cultivar’s hallmark character. In many markets and menus, you’ll see it listed as Larry OG (CBD), Larry OG CBD, or Lemon Larry CBD, signaling an intentional breeding focus on cannabidiol while preserving the Larry OG sensory signature.

This profile focuses specifically on Larry OG (CBD), as indicated by the target strain context, and compiles what growers, patients, and enthusiasts should know before choosing, cultivating, or using it. Because CBD-dominant or balanced OG phenotypes can vary by breeder and region, we organize current knowledge into clear sections and emphasize lab data wherever possible. Expect a deep dive into history, lineage, appearance, aroma, flavor, cannabinoid and terpene chemistry, experiential effects, potential therapeutic use, and a comprehensive cultivation guide built around measurable parameters and best practices.

For readers accustomed to high-THC OGs, the CBD variant offers a surprisingly familiar nose and flavor, paired with smoother, more functional daytime usability for many people. The balance often translates to reduced incidence of THC-related adverse effects like anxiety and short-term memory disruption while maintaining body ease and mood lift. Whether you are a medical patient looking for consistent symptom relief or a connoisseur wanting OG character without being overwhelmed, Larry OG (CBD) is engineered to bridge that gap.

History and Origins

The original Larry OG emerged from Southern California’s OG lineage in the mid-to-late 2000s and is frequently associated with Orange County’s OG circles. Known colloquially as Lemon Larry, it built a reputation for bright citrus notes layered over pine and fuel and a steady, couch-friendly potency. As OG cuts were shared and stabilized, Larry OG became one of the reliable, recognizable names in the wider OG family.

The CBD-focused evolution of Larry OG reflects a broader market shift from 2013 onward, when high-CBD cultivars like ACDC and Cannatonic demonstrated demand for non-intoxicating or balanced cannabis. Breeders began outcrossing popular terpene-rich favorites to CBD-dominant parents to achieve 1:1 or CBD-forward chemotypes. Larry OG (CBD) is one outcome of this movement, targeting consumers who love OG flavor/aroma but want a calmer, more clear-headed effect profile.

Because multiple breeders and nurseries have attempted CBD conversions of OG cuts, naming can vary and regional expressions of Larry OG (CBD) differ. Some programs focus on consistent 1:1 THC:CBD expressions, while others prioritize CBD-dominant outcomes with THC below 5%. As always, the reliable way to confirm what you have is third-party lab testing, as brand names alone do not guarantee chemotype.

Genetic Lineage and Breeding Rationale

In traditional accounts, Larry OG is often considered a phenotype within the OG Kush universe or a selection related to SFV OG (San Fernando Valley OG) lines. Some sources describe it as OG Kush crossed to an SFV OG cut, while others characterize it as a standout phenotype stabilized from OG seed populations. Regardless of which origin story you prefer, the strain’s sensory fingerprint aligns strongly with OG Kush family markers: lemon-citrus top notes, piney resin, and fuel-like undertones.

To produce Larry OG (CBD), breeders typically cross an authentic Larry OG cut with a CBD-dominant donor such as ACDC, Cannatonic, or a modern CBD parent (e.g., CD-1 type). The genetic goal is a BT/BD chemotype at the THCA/CBDA synthase locus—meaning plants produce both THCA and CBDA in roughly equal proportions. In many breeding programs, F1 offspring show chemotype segregation; subsequent selection and backcrossing hone the terpene profile back toward OG while preserving the desired CBD expression.

Statistically, early filial generations will present a mix of chemotypes: THC-dominant (BT/BT), CBD-dominant (BD/BD), and balanced (BT/BD). Breeders select and clone BT/BD or BD/BD keepers that also express OG-like terpene profiles, aiming for total terpene content in the 1.0–2.5% range by weight in finished flower. Over multiple rounds, the best performers are stabilized for higher uniformity in both cannabinoid ratios and Larry OG sensory traits.

This approach ensures that Larry OG (CBD) retains the lineage’s appeal—citrus, pine, and gas—while producing typical CBD-rich outcomes such as 6–12% CBD paired with 5–10% THC for balanced expressions. Some breeding lines push CBD dominance further, producing 12–18% CBD with <1–4% THC, though such phenotypes sometimes diverge from the classic OG nose. For consumers, this means different batches labeled Larry OG (CBD) may legitimately vary; lab certificates of analysis (COAs) are the definitive way to verify chemotype.

Appearance and Morphology

Larry OG (CBD) tends to form medium-dense, conical flowers with tight calyx stacking, a hallmark of OG lineage. Expect olive to forest-green bracts contrasted by amber-orange pistils that darken toward harvest. The trichome layer is typically abundant and glassy, giving the buds a frosted, sticky feel.

Leaf morphology generally skews toward hybrid OG traits: slightly narrower leaflets than pure broadleaf indicas and an overall medium-tall frame. Internodal spacing runs tight to moderate, allowing good bud stacking under high light while still accommodating airflow. Many growers note a 1.5x–2.0x stretch during the first two weeks of flowering.

Under ideal conditions, bag appeal is high, with pronounced calyx development and a visible resin sheen. Larry OG (CBD) can purple slightly in cooler nights (16–18°C) late in flower, although the classic phenotype remains green-dominant. Compared to ultra-dense indica buds, these flowers strike a balance between density and ease of dry-down, helping reduce mold risk if properly managed.

Aroma and Sensory Bouquet

The Larry OG (CBD) bouquet mirrors the original’s citrus-forward profile layered with pine and a light diesel-fuel nuance. Dominant limonene often leads with bright lemon, occasionally skewing toward candied lemon zest. Beneath that, beta-caryophyllene and myrcene contribute peppery warmth, damp earth, and soft herbal tones.

Pinene and humulene round out the nose with conifer resin and subtle hops-like dryness. In high-terpene expressions, total terpene content can reach 15–25 mg/g (1.5–2.5%), which translates to a deeply aromatic jar experience even at small volumes. Cured correctly, the aroma opens rapidly upon breaking buds, intensifying citrus and pine while revealing faint floral-lavender hints from linalool in some cuts.

Growers frequently note that pre-harvest flowers present a sharper, more solvent-like top note that softens during cure. The curing phase rebalances volatile monoterpenes and can bring forward sweeter, zestier elements after two to four weeks. Overly aggressive drying, however, can blunt these top notes, emphasizing earth and pepper at the expense of lemon brightness.

Flavor and Mouthfeel

On the palate, Larry OG (CBD) delivers lemon zest up front, quickly supported by pine sap, juniper, and a clean gassy undertone. The finish is peppery and slightly bitter-spicy, a signature of beta-caryophyllene. When vaporized, sweetness emerges more clearly and the lemon peel character becomes almost sherbet-like at lower temperatures (175–190°C).

Combustion accentuates the fuel and pepper components, especially if the flower is still slightly fresh. Properly cured batches exhibit a balanced, resinous mouthfeel without harshness, with smoothness improving markedly after 3–6 weeks in airtight glass at 58–62% RH. Users often report that the CBD-forward chemotype tastes rounder and less acrid at higher doses compared to THC-only OGs, likely due to differences in terpene retention and combustion behaviors.

In concentrates, the flavor skews brighter and more citrus-forward, with limonene and pinene dominating early pulls. Full-spectrum extracts preserve the pepper-pine finish, while distillate formulations can taste flatter unless re-terpened with a compatible OG blend. For culinary use, the lemon-pine top note can complement fatty bases and herbs like rosemary and thyme, though decarboxylation temperatures should be carefully managed to retain monoterpenes.

Cannabinoid Profile and Ratios

Larry OG (CBD) is intentionally selected for CBD expression while maintaining a recognizable OG terpene fingerprint. In balanced chemotypes, lab results commonly show 6–12% CBD and 5–10% THC in dried flower, with total cannabinoids around 15–22%. CBD-dominant phenotypes do occur, sometimes testing 12–18% CBD with THC below 1–4%, but these can diverge from the classic OG nose depending on breeding.

When reading COAs, remember that most laboratories report acidic precursors (THCA, CBDA) alongside neutral cannabinoids (THC, CBD). To estimate decarboxylated potency, multiply THCA by 0.877 and add the existing THC value (same for CBDA to CBD). For example, 10% THCA converts to roughly 8.77% THC after full decarb, minus processing losses.

Inhalation produces faster onset, typically within 5–10 minutes, with peak effects by 20–30 minutes and duration of 2–3 hours for many users. Oral ingestion produces slower onset, typically 60–120 minutes, with effects lasting 4–8 hours depending on dose and metabolism. Products labeled 1:1 (equal CBD:THC) tend to be well-tolerated by a broad swath of consumers compared to THC-dominant formulations, with observational data suggesting lower incidence of anxiety and tachycardia.

Batch variability is real, particularly with CBD reconstructions of legacy THC cultivars. Verified testing is essential, and cultivators focusing on 1:1 outcomes often phenotype-select and lab-screen multiple offspring to lock in ratios. If you require low intoxication, look for lots with CBD at least two times the THC content (2:1) or THC below 2% to minimize psychoactivity.

Terpene Profile and Secondary Metabolites

Across CBD-forward OG expressions, limonene, beta-caryophyllene, and myrcene frequently appear as the top three terpenes. In quality indoor flower, limonene may range around 0.3–0.8% by weight, caryophyllene 0.2–0.5%, and myrcene 0.2–0.8%, with total terpenes often falling between 1.0–2.5%. Secondary contributors commonly include alpha- and beta-pinene (0.05–0.3%), humulene (0.05–0.2%), and linalool (0.05–0.2%).

From a pharmacology perspective, beta-caryophyllene is notable as a selective CB2 receptor agonist in peripheral tissues, potentially modulating inflammation pathways without central intoxication. Limonene has been studied for mood-elevating and anxiolytic properties in preclinical and small human studies, though results vary. Myrcene is frequently associated with sedative and muscle-relaxant qualities, especially when combined with cannabinoids.

Pinene adds a crisp, clarifying edge and has been studied for bronchodilatory effects, which some users interpret subjectively as a sense of open breathing. Linalool’s floral-lavender element can support calm and restfulness, although in many Larry OG (CBD) cuts it remains a minor component. The overall terpene stack helps explain why Larry OG (CBD) often feels composed and balanced, offering calm without heavy cognitive fog for many users.

High terpene levels also correlate with stronger aroma and flavor persistence after grinding. In storage testing, samples kept at 58–62% RH in airtight glass and under 20°C retain more monoterpenes over 60 days than jars exposed to light or temperature swings. If you care about the lemon-forward personality of Larry OG (CBD), protect the terpenes as deliberately as you do cannabinoids.

Experiential Effects and Use Cases

Consumers typically describe Larry OG (CBD) as calm, clear, and physically easing, with a gentle head effect relative to THC-dominant OGs. The CBD presence tends to moderate THC’s sharp edges, yielding a smoother psychological profile with fewer reports of racing thoughts at moderate doses. At 1:1 ratios, new users often find a sweet spot where muscle tension decreases and mood lifts without pronounced impairment.

Inhaled effects arrive within minutes, making it easy to titrate to comfort. Many users report a tranquil body feel paired with light euphoria and improved stress resilience, lasting two to three hours. At higher doses or with more THC-leaning batches, sedation becomes more noticeable, especially later in the day.

Functionally, Larry OG (CBD) is well-suited to low-stress evenings, creative work that doesn’t demand rapid short-term memory, or social settings where you want to stay grounded. Athletes and active users sometimes choose it for post-exercise recovery due to perceived muscle relaxation and reduced soreness. For those sensitive to THC, look for CBD-dominant lots or microdose inhalations to maintain clarity.

As always, individual responses vary based on physiology, tolerance, and context. Set and setting influence outcomes, and hydration, food intake, and sleep can all shift your experience. Start low, reassess after 20–30 minutes when inhaling, and avoid driving or operating machinery while effects are active.

Potential Medical Applications and Evidence

Larry OG (CBD) is not a medical product, but its CBD-forward or balanced cannabinoid profile aligns with several areas of clinical interest. Balanced THC:CBD formulations have been investigated for neuropathic pain, multiple sclerosis spasticity, and cancer-related symptoms in controlled trials. For example, a standardized 1:1 THC:CBD oromucosal spray (nabiximols) has demonstrated clinically meaningful spasticity reduction in a subset of MS patients, with responder rates around 40% achieving at least a 30% improvement in some analyses.

In anxiety research, CBD has shown promise for situational anxiety at moderate-to-high single doses. A 2011 study in individuals with social anxiety disorder found that a single 600 mg dose of CBD reduced anxiety during a public speaking simulation compared with placebo. A 2019 retrospective case series reported that 79% of 72 adult patients experienced decreased anxiety within the first month and 67% showed improved sleep, though results fluctuated over time and study design limits interpretation.

Pain is a complex, multifactorial domain, but balanced THC:CBD preparations may help some patients, particularly for neuropathic components. Observational programs often report improved tolerability of 1:1 products compared to THC-only, with fewer reports of anxiety, dysphoria, or palpitations at comparable analgesic levels. Beta-caryophyllene’s CB2 activity and CBD’s interactions with TRPV1 and 5-HT receptors may contribute to perceived benefits in inflammatory and nociceptive contexts.

Sleep outcomes with CBD are mixed and appear dose-dependent. Lower doses of CBD can be alerting for some, while higher doses combined with THC and myrcene-rich terpene profiles may support sleep onset. Larry OG (CBD), especially in evening use and at doses that lean sedative, is commonly chosen anecdotally to help unwind before bed.

As with all cannabis use, medical outcomes depend heavily on dose, ratio, route, and individual biology. Work with a qualified clinician, track symptom changes, and prefer batches with verified COAs so you can match effects to cannabinoid and terpene data. If you require minimal intoxication, target products where CBD equals or exceeds THC, and consider vaporization or tinctures for precise titration.

Comprehensive Cultivation Guide

Larry OG (CBD) grows like a classic OG hybrid with moderate vigor, benefiting from structured training and consistent environment control. Indoors, aim for 24–28°C daytime and 18–22°C nighttime temperatures duri